Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
Public ClinicalTrials.gov record NCT01257230. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety Over 48 Weeks of Orally Inhaled Tiotropium Bromide (2.5 and 5 µg Once Daily ) Delivered by the Respimat® Inhaler in Adolescents (12 to 17 Years Old) With Moderate Persistent Asthma.
Study identification
- NCT ID
- NCT01257230
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 398 participants
Conditions and interventions
Conditions
Interventions
- tiotropium Respimat low dose Drug
- placebo Respimat Drug
- tiotropium Respimat high dose Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2010
- Primary completion
- Nov 30, 2013
- Completion
- Nov 30, 2013
- Last update posted
- Sep 4, 2014
2010 – 2013
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.444.01004 Boehringer Ingelheim Investigational Site | Plymouth | Minnesota | — | — |
| 205.444.01005 Boehringer Ingelheim Investigational Site | Columbia | Missouri | — | — |
| 205.444.01001 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.444.01014 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 205.444.01002 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 205.444.01012 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 205.444.01013 Boehringer Ingelheim Investigational Site | El Paso | Texas | — | — |
| 205.444.01003 Boehringer Ingelheim Investigational Site | South Burlington | Vermont | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01257230, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2014 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01257230 live on ClinicalTrials.gov.